|
Volumn 45, Issue 19, 2002, Pages 4094-4096
|
Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction
a a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLIC GMP;
PHOSPHODIESTERASE;
PHOSPHODIESTERASE I;
PHOSPHODIESTERASE INHIBITOR;
PHOSPHODIESTERASE IV;
PHOSPHODIESTERASE V;
PYRIMIDINYLPYRROLOQUINOLONE DERIVATIVE;
QUINOLONE DERIVATIVE;
SILDENAFIL;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
CONTROLLED STUDY;
DOG;
DRUG BIOAVAILABILITY;
DRUG EFFICACY;
DRUG POTENCY;
DRUG STRUCTURE;
ERECTILE DYSFUNCTION;
MALE;
NONHUMAN;
PENIS ERECTION;
RAT;
STRUCTURE ACTIVITY RELATION;
3',5'-CYCLIC-GMP PHOSPHODIESTERASE;
ADMINISTRATION, ORAL;
ANIMALS;
BIOLOGICAL AVAILABILITY;
DOGS;
ENZYME INHIBITORS;
IMPOTENCE;
MALE;
QUINOLONES;
RATS;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 0037068429
PISSN: 00222623
EISSN: None
Source Type: Journal
DOI: 10.1021/jm025545d Document Type: Article |
Times cited : (23)
|
References (20)
|